Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Clario acquires WCG's neuroscience-focused clinical outcome assessment business
(7h)
Insilico Medicine raises $110M for new trials and robotic helping hands
(9h)
J&J’s Monarch bronchoscopy robot cleared by FDA to connect to live CT scans
(10h)
Manufacturer fuels Swiss biotech’s next-gen vaccine portfolio in new investment deal
(10h)
GSK posts data on HIV assets vying for roles in 6-month combo
(12h)
Harbour BioMed launches new obesity biotech on mission to preserve muscle mass
(13h)
Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer
(14h)
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to co-develop amylin asset
(15h)
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
(15h)
Boehringer Ingelheim teams with Veeva to launch new R&D platform One Medicine
(1d)
BioPharma Dive
Roche broadens obesity drug plans with $1.65B Zealand deal
(8h)
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
(8h)
Flagship startup raises $200M in pursuit of ‘scientific superintelligence’
(9h)
Ono pays $280M to license Ionis rare disease drug
(9h)
Viking inks CordenPharma deal to boost obesity drug supply
(1d)
Merck opens $1B vaccine plant in North Carolina
(1d)
Arvinas gets positive breast cancer data, but finds differentiation a hard sell
(1d)
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
(1d)
Douglas Kelly, deputy science director at FDA’s device center, leaves agency
(1d)
Healthcare tackles AI oversight with no aid from Trump administration
(2d)
Endpoints News*
Mallinckrodt and Endo exploring a $7B merger — report
(4h)
Why Gilead could lose its HIV product hopping case
(5h)
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV drug
(9h)
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatment
(9h)
Ascletis’ not-so-great weight loss data; Vivace’s $35M Series D
(10h)
Insilico nabs $110M Series E for AI drug discovery after stalling Hong Kong IPO plans
(10h)
Viking Therapeutics taps CordenPharma to manufacture its obesity drugs
(10h)
Legend to double Carvykti production as it targets blockbuster status
(13h)
Ono licenses rare blood disease drug from Ionis for $280M upfront
(13h)
Zealand partners with Roche on petrelintide in a deal worth $5.3B
(16h)
BioSpace
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
(11h)
Good Day for Gardasil as Merck Wins Safety Suit, Drops $1B for Manufacturing Push
(11h)
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
(11h)
Ionis Sends Polycythemia Vera Drug to Ono in Licensing Deal Worth Nearly $1B Biobucks
(12h)
COVID Reflections, Novo’s Next-Gen Weight Loss Struggles, Another Depression Miss, More
(14h)
Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs
(17h)
16 Years And 3 Texas Two-Steps Later, J&J’s Talc Lawsuit Awaits Key Ruling
(18h)
Viking Secures 1B Supply of Obesity Pill Candidate With $150M Prepayment Deal
(1d)
Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug
(1d)
The Shape of a Pandemic: Boom, Bust and Recover
(1d)
Stat News*
CDC’s reported study on vaccines and autism could test RFK Jr.’s pledges to a key senator
(3h)
Harvard Medical physicians sue over removal of articles mentioning ‘LGBTQ’ from government website
(6h)
Telehealth platforms in senators’ crosshairs over relationship with Eli Lilly, Pfizer
(8h)
Why health experts fear the West Texas measles outbreak may be much larger than reported
(9h)
Food insecurity in early adulthood raises the risk of heart disease, long-term study shows
(9h)
Should health care providers tell patients they are using AI?
(9h)
Lilly CEO got a big payday (and an Olympics treat)
(10h)
Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
(11h)
SAMHSA employees detail an agency in shambles
(11h)
Warren asks HHS watchdog to investigate GSK over its asthma inhaler maneuvers
(14h)
BioPharma Trend
Insilico Medicine Raises $110M to Advance AI Drug Design, Unveils its Humanoid Lab Robot
(5h)
Lila Sciences Raises $200M to Automate Scientific Discovery with AI and Robotics
(1d)
U.S. Judge Blocks NIH Grant Funding Cuts Amid Ongoing Litigation
(6d)
AI-Powered Immune Mapping Company Appoints Ex-Pfizer R&D Chief to Its Board
(6d)
Cortical Labs Launches $35K Biological Computer Built on Human Brain Cells
(1w)
Cortical Labs Introduces Biological Computer Built on Human Brain Cells
(1w)
Novo Nordisk and Gensaic Collaborate on Tissue-Targeted Therapies for Cardiometabolic Diseases
(1w)
Google Cloud Introduces Multimodal AI for Healthcare at HIMSS 2025
(1w)
Vevo Therapeutics Open-Sources Largest Single-Cell Dataset with Arc Institute
(2w)
AI in Drug Safety: From Concept to Reality, The Industry's Path Forward
(2w)
Labiotech.EU
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
(10h)
The gender gap in clinical trials: Why women are still underrepresented
(1d)
23andMe: the collapse of a genomics giant
(2d)
Catalonia: A biotech hub going from strength to strength, with Barcelona at its core
(5d)
[Rebroadcast] How AI immune system mapping can boost drug discovery
(5d)
Top biotech deals of February 2025
(6d)
Seven biotech companies keeping Taiwan dynamic in 2025
(1w)
The biggest biotech funding rounds in February 2025
(1w)
Rare Disease Day: seven drugs awaiting approval in 2025
(2w)
The TCR-T cell therapies of tomorrow
(2w)
GEN News
With $110M Financing Complete, Insilico Eyes Platform, Pipeline Progress
(3h)
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform Into Its Process Development Operations
(5h)
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
(7h)
Fungus-Based Nanoparticles Can Battle Infections and Cancer
(8h)
AI, IoT, and the Future of Biopharma Manufacturing
(8h)
Adherent Cells a Sticking Point? Novel Culturing Tech Could Help
(8h)
Comprehensive Allele-Specific DNA Methylation Atlas Developed
(14h)
BMS to Acquire Abecma Partner 2seventy bio for $286M
(1d)
Gut Bacteria that Convert Bile Acids Improve Recovery from Colonic Injury
(1d)
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
(1d)
Cure Today
Tedopi Cancer Vaccine Meets Trial End Point For Pancreatic Cancer
(3h)
Bringing Together the CAR T-Cell Therapy Community
(5h)
Nutrition is Key Following a Cancer Diagnosis
(5h)
The Leukemia & Lymphoma Society is Helping Patients With Medial Debt
(5h)
Discussing the Mission of CURE® With Our Former and New Editors-In-Chief
(5h)
Discussing the Mission of CURE With Our Former and New Editors-In-Chief
(5h)
Four Things to Remember When Both Spouses Have Cancer
(7h)
First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer
(8h)
Targeted Axillary Dissection Offers a Precise Option in Breast Cancer
(9h)
RECKGIST Score May Predict Recurrence in Neurofibromatosis Type 1 GISTs
(11h)
Contract Pharma*
Advarra Launches Oncology Research Pulse
(5h)
Gattefossé Earns Three U.S. Plant Certifications in Lufkin, TX
(6h)
Shift Bioscience Makes Key Leadership Appointments
(10h)
Emergent BioSolutions and Rocketvax Announce Investment Agreement
(10h)
Roche, Zealand Pharma Partner to Co-Develop & Co-Commercialize Obesity Therapy
(10h)
Vetter boosts pharmaceutical storage capacity with major warehouse expansion
(10h)
LGM Pharma to Invest Over $6M to Expand Rosenberg Facility
(11h)
Celonic Integrates Merck’s Breez Micro-Bioreactor Platform
(11h)
Harbour BioMed Launches Élancé Therapeutics
(11h)
Standardization in Large-Volume Subcutaneous Delivery: A Collaborative Approach
(12h)
The Pharma Letter*
Ono partners with Ionis for sapablursen
(9h)
Gedea’s vaginal tablet trial delivers
(9h)
Boehringer launches unified platform with Veeva
(9h)
ViiV boosted by Phase IIa data for VH184 and VH499
(9h)
Roche licenses obesity candidate from Zealand Pharma
(10h)
Viking shares slip after manufacturing deal announced
(10h)
Geron Corp reveals CEO is leaving
(11h)
Purespring Therapeutics names new CEO
(12h)
Pierre Fabre and RedRidge Bio link up on biparatopic antibodies
(13h)
Fondazione Telethon submits BLA for etuvetidigene autotemcel
(13h)
Targeted Oncology
mHSPC Regimens Are Distinguished by Drug Interactions and Disease Volume
(3h)
Actimab-A Triplet Trial Launches in Frontline AML
(5h)
HER2DX Test Transforms Treatment Decisions in HER2+ Breast Cancer
(7h)
Orlowski Discusses Treatment Path Through Successive Relapses of Multiple Myeloma
(9h)
Phase 2 Trial of OSE2101 in Advanced PDAC Meets Primary End Point
(10h)
Clinical Perspectives for Treatment of R/M NPC
(10h)
Treatment Paradigms in R/M NPC: Evolving Role of Systemic Immunotherapy
(10h)
Insights From JUPITER-02: Plasma EBV Levels and Toripalimab in R/M NPC
(10h)
Treatment Approaches in Metastatic NPC: First-Line Toripalimab + Gemcitabine/Cisplatin
(10h)
A 53-Year-Old Woman With Metastatic NPC
(10h)
MedWatch*
MSD invests USD 1bn to expand US vaccine production
(11h)
Billion-dollar deal offers additional opportunity – but Zealand Pharma CEO maintains focus on "crown jewel"
(11h)
Billion-dollar deal offers additional opportunity – but Zealand Pharma CEO maintains focus on crown jewel
(11h)
Reactions to EU critical medicines plan are pouring in – regional joint procurement groups delighted
(11h)
Novo Nordisk stock halved since peak: Lost USD 336bn in market capitalization
(13h)
EU Commission builds on COVID-19 pandemic experience: Proposes joint procurement of critical medicines
(14h)
Zealand Pharma enters obesity collaboration with Roche and gets USD 1.4bn in cash
(15h)
Gubra partner will test monthly dose of weight-loss candidate
(1d)
Abbvie will test monthly dose of Gubra's weight-loss candidate
(1d)
Compounders suffer defeat in Eli Lilly copycat drug case
(1d)
In The Pipeline
A Bifunctional Degrader Reads Out in Phase 3
(5h)
New Synthetic Antibiotics
(1d)
Single-Base Editing Seems to Work
(2d)
Bird is the (Geomagnetic) Word
(6d)
The Continuing Crisis, Part VII: An Overview
(1w)
The Continuing Crisis, Part VI: Rare Diseases at the FDA and More
(1w)
Progress on RNA-Based Cancer Vaccines
(1w)
The Thiazide Target, At Last
(2w)
Neurodegeneration Might Come Down to RNA
(2w)
The Continuing Crisis, Part V: What the NIH Is Telling Its People
(3w)
Pharmaphorum
Roche builds in obesity with $5.3bn Zealand licensing deal
(10h)
Gates-backed game aims to raise HPV awareness in Africa
(11h)
EU proposes legislation to bolster medicines supply chain
(12h)
Merck MS tablet set for wider use by NHS in England
(13h)
MSD opens $1bn plant for HPV vaccine in the US
(14h)
Pfizer's new drug data in breast cancer draws muted response
(1d)
Scientific 'superintelligence' firm Lila launches with $200m
(1d)
J&J abandons work with Genmab on Darzalex successor
(1d)
NHS England facing major job losses to reduce DHSC 'overlap'
(1d)
BMS absorbs CAR-T partner 2seventy bio for $286m
(1d)
Drug Discovery Weekly
Pharma/biotech biparatopic antibody collaboration agreed
(8h)
A global overview of therapeutic antibody development
(8h)
Financing secured for cancer drug targeting the Hippo pathway
(9h)
Trial evaluating treatment for R/R mature B-cell lymphomas
(11h)
Proteasome discovery “opens new frontier for personalised treatments”
(13h)
Neuropathic corneal pain treatment filed with FDA
(13h)
Download the Article: The discovery and evolution of antibody formats
(14h)
Register now: Learn how to implement a successful data automation strategy
(15h)
Webinar: Implement a successful data automation strategy
(15h)
Advancing cancer therapy with antibody-drug conjugates
(15h)
Reddit Biotech
Laid off from Cepheid and panicking
(3h)
Preferred candidate, then silence
(4h)
Is it a bad move to go into gene editing right now?
(4h)
Seeking advice as an MD and chemist
(4h)
$25 /hr looking for BS in STEM and programming skills…
(5h)
Last stage interview
(5h)
Masters program recommendations
(6h)
Why is the job market so hot right now?
(6h)
Is biotechnoligy more bioligy related ir more chemistry related?
(6h)
Internal job posting confusion
(6h)
Google News Biotech
San Diego's Biotech Scene Flourishes as Biotheryx Moves into Award-Winning Elements Campus - Hoodline
(2h)
Aurea Biotech Announces U.S. Distribution of ATTIVA - PR.com
(4h)
Portage Biotech Resumes Patient Enrollment In Final Cohort Of Dose Escalation Stage For PORT-6 - Nasdaq
(5h)
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com India
(6h)
TScan Therapeutics’ SWOT analysis: biotech stock navigates clinical milestones - Investing.com
(6h)
Montgomery College Approved to Sponsor Biotechnology Apprenticeships - Montgomery Community Media
(7h)
Biotech Alert: Searches spiking for these stocks today - TipRanks
(7h)
EmTech Italy 2025: The Challenge of AI in biotech - Born2Invest
(8h)
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
(8h)
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV - BioPharma Dive
(8h)
* May require subscription